Solana SARS-CoV-2 Assay Kit with NP Swabs and Transport Media


(96 Tests per Kit, Controls, 100 Nasopharyngeal Swabs, 100 Universal Transport Media)

FDA Emergency Use Authorization

The Solana SARS-CoV-2 Assay is an isothermal Reverse Transcriptase - Helicase-Dependent Amplification (RT-HDA) assay intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal (NP) and nasal (NS) swab specimens from individuals suspected of COVID-19 by their healthcare provider.

Molecular identification of SARS-CoV-2 occurs by the use of targeting highly conserved regions of the SARS-CoV-2 virus non-structural Polyprotein (pp1ab).

The assay consists of two major steps: (1) specimen preparation, and (2) amplification and detection of target sequences specific to SARS-CoV-2 using isothermal Reverse Transcriptase — Helicase-Dependent Amplification (RT-HDA) in the presence of target-specific fluorescence probes which is performed in the Solana instrument.

Results are displayed on the touchscreen, can be saved to the instrument, printed, and are capable of being sent to the LIS and exported through one of Solana’s five USB ports. Solana SARS-CoV-2 Assay is also supported by the power of Virena®.

Additional positive controls (QDL-M5301) and negative controls (QDL-M5203) can be purchased upon request.

REFUND POLICY for COVID-19 Products: The standard CLIAwaived refund policy does not apply for COVID-19 rapid tests. All sales are final once goods are shipped and in transit with courier. NO EXCHANGES OR REFUNDS WILL BE MADE.

Request a Quote

Features & Benefits

Feature Benefit

RT-HDA technology

Rapid method of isothermal nucleic acid amplification that does not require thermal cycler

Frozen Master Mix

Easy-to-use format, just thaw Master Mix before use (see Package Insert)

Small, easy-to-use instrument

Eliminates the need for dedicated molecular space and costly capital equipment, allowing for testing in smaller labs

CLIA moderately complex

Requires minimal training


Process Buffer 2˚C to 8˚C storage, Master Mix -70˚C or below

Long shelf life

6 months from date of manufacture

Room temperature set up

No ice or cooling block required

Product Specifications

Sample type

Nasal swabs and nasopharyngeal swabs in transport media* obtained from patients suspected of COVID-19

Time to results

Approximately 30 minutes

Reagent storage conditions

Process Buffer Reaction Tubes 2˚C to 8˚C and Master Mix -70˚C or below

Controls storage conditions

2°C to 8°C

Sample preparation storage conditions

Specimens should be collected, transported, stored, and processed according to CLSI M41-A. Specimens should be stored at 2°C to 8°C until tested.


Specimens collected in BD/Copan UTM are stable at room temperature (RT), 2°C to 8°C or -70°C or below for up to 4 days. Specimens collected in the CDC Viral Transport Medium should be stored at 2°C to 8°C for up to 72 hours after collection.

Nasal: 97.2%
Nasopharyngeal: 100%
Nasal: 100%
Nasopharyngeal: 96.9%


*BD/Copan UTM, CDC Viral Transport Media

© 2020 Cliawaived, Inc. All Rights Reserved. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.